QA/QC总监
泰州迈博太科药业有限公司
- 公司规模:150-500人
- 公司性质:外资(非欧美)
- 公司行业:制药/生物工程
职位信息
- 发布日期:2017-07-04
- 工作地点:泰州
- 招聘人数:1人
- 职位月薪:1.5-2.5万/月
- 职位类别:药品生产/质量管理
职位描述
职位描述:
QA总监:在GMP药厂QA总监职位上有1年以上工作经历,产品为基因工程药物、非最终灭菌的无菌制剂,任职QA总监期间经历过新版GMP检查者为佳。
质量总监:在QA总监的基础上,应加上QC方面的任职经历(蛋白类药物);或者有特定质量总监的任职经历(蛋白类药物,介入QC事务程度较深)。
举报
分享
QA总监:在GMP药厂QA总监职位上有1年以上工作经历,产品为基因工程药物、非最终灭菌的无菌制剂,任职QA总监期间经历过新版GMP检查者为佳。
质量总监:在QA总监的基础上,应加上QC方面的任职经历(蛋白类药物);或者有特定质量总监的任职经历(蛋白类药物,介入QC事务程度较深)。
职能类别: 药品生产/质量管理
公司介绍
泰州迈博太科药业有限公司于2015年入驻泰州市中国医药城,注册资本2000万美元。公司主要从事单抗药物生产,投资总额2亿美元,拟建厂房面积3万余平方,建设符合GMP标准的国际先进的抗体药物制备体系,以期打造国内抗体药物生产高地。迈博太科药业由上海张江生物技术有限公司(抗体药物与靶向治疗国家重点实验室)抗体研发团队提供一站式平台服务,致力于实现一系列重量级国家创新抗体药物的产业化。现有品种:治疗结直肠癌的重组抗EGFR人鼠嵌合单克隆抗体,治疗银屑病的重组人LFA3-抗体融合蛋白等。
Taizhou Mabtech Pharmaceutical Co., Ltd. joined the China Medical City (CMC) in 2015 with registered capital of USD 20 million, expanding a national highland for monoclonal antibody medicine manufacturing by establishing internationally advanced antibody medicine manufacture system with adopted cGMP standards, with a total investment of USD 200 million. Supported by the one-stop platform for therapeutic mAb medicine development provided by ZJ-Bio R&D Team (State Key Laboratory of Antibody Medicine and Targeted Therapy), Taizhou Mabtech Pharmaceutics Co., Ltd is dedicated to industrialization of a series of “blockbuster” innovative antibody drugs. Existing varieties: recombinant anti-EGFR human/mouse-chimeric monoclonal antibody for the treatment of colorectal cancer, recombinant human LFA3-antibody fusion protein for the treatment of psoriasis , et al.
视 频 资 料
http://www.tz2100.com/news/dqxw/gx/2015/4/9/1428544031298.shtml
Taizhou Mabtech Pharmaceutical Co., Ltd. joined the China Medical City (CMC) in 2015 with registered capital of USD 20 million, expanding a national highland for monoclonal antibody medicine manufacturing by establishing internationally advanced antibody medicine manufacture system with adopted cGMP standards, with a total investment of USD 200 million. Supported by the one-stop platform for therapeutic mAb medicine development provided by ZJ-Bio R&D Team (State Key Laboratory of Antibody Medicine and Targeted Therapy), Taizhou Mabtech Pharmaceutics Co., Ltd is dedicated to industrialization of a series of “blockbuster” innovative antibody drugs. Existing varieties: recombinant anti-EGFR human/mouse-chimeric monoclonal antibody for the treatment of colorectal cancer, recombinant human LFA3-antibody fusion protein for the treatment of psoriasis , et al.
视 频 资 料
http://www.tz2100.com/news/dqxw/gx/2015/4/9/1428544031298.shtml
联系方式
- Email:hr.taizhou@sinomabtech.com
- 公司地址:上班地址:泰州医药高新技术产业园